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We sought to investigate the prevalence, functional characteristics, and clinical significance of right 
ventricular (RV) involvement in patients with hypertrophic cardiomyopathy (HCM). A total of 256 
patients with HCM who underwent both cardiac magnetic resonance (CMR) imaging and transthoracic 
echocardiography within 6 months of each other were retrospectively analysed. RV involvement was 
defined as an increased RV wall thickness ≥ 7 mm on CMR in the segments of the RV free wall. Primary 
outcomes were defined as the composite of all‑cause death, heart transplantation, and unplanned 
cardiovascular admission. Thirty‑seven (14.4%) patients showed RV involvement. Patients with RV 
involvement showed a significantly higher left ventricular (LV) maximal wall thickness and left atrial 
volume index. Multivariate Cox model revealed that RV involvement was independently associated 
with primary outcomes (HR: 2.30, p = 0.024). In a subgroup analysis of patients with speckle tracking 
echocardiography (n = 190), those with RV involvement had significantly more impaired RV strain, 
which was independently associated with primary outcomes. RV involvement in patients with HCM 
correlated with more advanced LV structure and biventricular dysfunction, suggesting an indicator of 
severe HCM. RV involvement and impaired RV strain have a prognostic value related to clinical adverse 
events in patients with HCM.
Many studies on hypertrophic cardiomyopathy (HCM) have focused on the left ventricle (LV). Maximal left 
ventricular wall thickness, left ventricular outflow tract (LVOT) obstruction, LV apical aneurysm, and late gado-
linium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging are suggested risk factors for sudden 
cardiac death (SCD) in  HCM1–3.
On the other hand, the right ventricle (RV) relatively has long been neglected, perhaps because RV is not 
considered a major risk factor for SCD related to HCM, and it is difficult to measure RV thickness accurately 
by transthoracic echocardiography (TTE). A few studies have recently reported the prevalence and clinical 
significance of RV involvement using CMR  imaging4,5 and clinical/subclinical RV dysfunction in patients with 
 HCM6,7. Although these results suggest that the presence or absence of RV involvement may be important for 
the current disease status and clinical prognosis in patients with HCM, the prevalence, structural and functional 
characteristics, and prognostic significance of RV involvement in patients with HCM are still ambiguous. There-
fore, the objectives of this study were to identify the prevalence of RV involvement in patients with HCM using 
CMR imaging and to investigate whether RV involvement and RV dysfunction have prognostic significance in 
determining clinical outcomes.
OPEN
1Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Republic of Korea. 2Department of Radiology, Research Institute of Radiological 
Science, Severance Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, 
Republic of Korea. *email: GRHONG@yuhs.ac
2
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21908  | https://doi.org/10.1038/s41598-020-78945-4
www.nature.com/scientificreports/
Results
Prevalence and baseline characteristics. Among the 256 patients with HCM, 37 (14.4%) with RV 
involvement were identified by CMR. Substantial interobserver agreement was achieved for the evaluation of 
RV involvement (kappa value, 0.89). Baseline characteristics of the study population are presented in Table 1. 
Patients’ mean age was 53.1 ± 14.2  years, 180 (70.3%) were men, and 42 (16.4%) were diagnosed with atrial 
fibrillation (AF). Patients with RV involvement had a higher percentage of AF and had more frequently received 
an implantable cardioverter defibrillator (ICD) than those without RV involvement. Patients with RV involve-
ment showed a significantly higher LVMWT, higher left atrial volume index (LAVI) and higher E/e’ than those 
without RV involvement. CMR imaging data showed that the LVMWT and LV end systolic volumes were signifi-
cantly higher in patients with RV involvement than in those without. RV LGE was also predominantly detected 
in patients with RV involvement.
Clinical outcomes. During the follow-up period, there were 33 primary outcomes, including all-cause 
death (n = 3), heart transplantation (n = 1), and unplanned cardiovascular admission (n = 29). Two patients had 
sudden cardiac death, and one patient died from lung cancer. Among the 29 cardiovascular hospitalizations, 10 
were admitted for heart failure, 5 had ongoing and recurrent angina, 5 were admitted for atrial tachyarrhythmia, 
2 were admitted for ventricular tachyarrhythmia, 4 had a sudden collapse, and 3 had stroke. Table 2 shows uni-
Table 1.  Baseline characteristics of the study population. RV right ventricle, LV left ventricle, BMI body 
mass index, SCD sudden cardiac death, RAS renin–angiotensin system, LVEF LV ejection fraction, LAVI left 
atrial volume index, LVOT left ventricular outflow tract, LS longitudinal strain, GLS global LS, MR magnetic 
resonance, EDV end diastolic volume, ESV end systolic volume, LGE late gadolinium enhancement. *P value 
between patients with RV involvement and without RV involvement.
Total patients (n = 256) No RV involvement (n = 219) RV involvement (n = 37) P value*
Demographic and clinical data
Age, year 53.1 ± 14.2 53.4 ± 14.3 51.5 ± 14.1 0.454
Male sex, n (%) 180 (70.3) 150 (68.8) 29 (78.4) 0.334
BMI, kg/m2 24.8 ± 3.2 24.9 ± 3.2 24.1 ± 3.3 0.153
Hypertension, n (%) 189 (73.8) 164 (74.9) 25 (67.6) 0.463
Diabetes mellitus, n (%) 48 (18.8) 40 (18.3) 8 (21.6) 0.798
Dyslipidemia, n (%) 87 (34.0) 70 (32.0) 17 (45.9) 0.141
Atrial fibrillation, n (%) 42 (16.4) 30 (13.7) 12 (32.4) 0.009
Family history of SCD, n (%) 40 (15.6) 33 (15.1) 7 (18.9) 0.725
ICD, n (%) 21 (8.2) 13 (5.9) 8 (21.6) 0.004
Syncope, n (%) 34 (13.3) 25 (11.4) 9 (24.3) 0.060
Beta blocker, n (%) 127 (49.6) 110 (50.2) 17 (45.9) 0.761
Calcium channer blocker, n (%) 54 (21.1) 43 (19.6) 11 (29.7) 0.240
RAS blocker, n (%) 111 (43.4) 102 (46.6) 9 (24.3) 0.019
Aspirin, n (%) 62 (24.2) 49 (22.4) 13 (35.1) 0.142
Statin, n (%) 83 (32.4) 65 (29.7) 17 (45.9) 0.077
Echocardiographic data
LVEF, % 68.6 ± 8.7 68.9 ± 8.2 66.8 ± 11.0 0.277
LAVI, mL/m2 41.6 ± 15.9 40.3 ± 14.8 49.1 ± 20.0 0.014
RV systolic pressure, mm Hg 27.0 ± 7.0 26.6 ± 6.6 29.3 ± 8.8 0.080
E/e’ 15.4 ± 7.0 15.1 ± 7.1 17.5 ± 6.5 0.051
LV maximal thickness, mm 21.2 ± 4.7 20.6 ± 4.3 24.6 ± 5.2  < .001
RV thickness, mm 4.4 ± 1.4 4.1 ± 0.9 5.8 ± 2.5  < .001
LVOT obstruction, n (%) 62 (24.2) 52 (23.7) 10 (27.0) 0.823
Cardiac MR data
LV maximal thickness, mm 21.6 ± 5.2 21.2 ± 5.0 23.8 ± 5.7 0.006
RV maximal thickness, mm 5.4 ± 1.8 4.8 ± 0.6 9.0 ± 2.2  < .001
LVEDV, ml 143.8 ± 34.2 143.6 ± 33.3 144.9 ± 39.6 0.842
LVESV, ml 48.1 ± 19.7 46.9 ± 19.3 55.6 ± 21.2 0.017
LVEF, % 67.5 ± 8.8 68.3 ± 8.2 62.6 ± 10.3  < .001
RVEDV, ml 131.3 ± 66.5 131.8 ± 70.2 128.4 ± 37.9 0.681
RVESV, ml 50.8 ± 20.5 50.8 ± 20.3 50.9 ± 21.5 0.983
RVEF, % 61.2 ± 8.9 61.2 ± 8.7 61.0 ± 10.5 0.896
LV LGE, n (%) 236 (92.2) 199 (90.9) 37 (100.0) 0.113
RV LGE, n (%) 26 (10.2) 5 (2.3) 21 (56.8)  < .001
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variate and multivariate Cox proportional hazard models for the primary outcomes in total patient population 
(n = 256). In univariate Cox proportional hazard analysis, the presence of AF, a history of unexplained syncope, 
increased LAVI, elevated RVSP, higher E/e’, and lower LVEF measured by CMR were significantly associated 
with a higher risk of primary outcomes. In multivariate analysis, the presence of AF, a history of unexplained 
syncope, higher E/e’, lower LVEF measured by CMR, and the presence of RV involvement were independently 
associated with primary outcomes. Figure 1A shows Kaplan–Meier curves for primary outcome-free survival 
according to the presence of RV involvement. There was a significantly higher probability of primary outcomes 
in patients with RV involvement (p < 0.001). In a subgroup analysis of 190 patients with analysable speckle track-
ing echocardiography, 79 (41.6%) had impaired RV free wall LS (> − 20%) as shown in Table 3. Impaired RV free 
wall LS (hazard ratio [HR] = 3.07, 95% confidence interval [CI] = 1.16–8.09, p = 0.023), higher E/e’, and lower 
LVEF were independent factors associated with primary outcomes (Table 4). Kaplan–Meier curves for primary 
outcome-free survival, according to RV free wall LS, revealed that the most deleterious primary outcomes were 
in patients with impaired RV free wall LS, as shown in Fig. 1B.
RV dysfunction. In a subgroup analysis, 190 patients with speckle tracking echocardiography were analysed 
separately to compare RV mechanical function and its association with RV involvement. Supplementary Table 1 
shows baseline characteristics of the 190 patients. Patients with RV involvement had more impaired LV GLS, RV 
GLS, RV septal wall LS, and RV free wall LS than those without RV involvement. RV GLS (R = 0.345, p < 0.001) 
and RV free wall LS (R = 0.310, p < 0.001) were significantly correlated with RV maximal wall thickness meas-
ured on CMR imaging (see Fig. 2A,B). In multivariate logistic regression analysis for echocardiographic param-
eters associated with RV involvement, RV free wall LS (odds ratio [OR] = 1.01, 95% CI = 1.00–1.01, p = 0.046), 
RV thickness (OR = 1.09, 95% CI = 1.06–1.12, p < 0.001), LV GLS (OR = 1.01, 95% CI = 1.00–1.03, p = 0.034), 
and LVMWT (OR = 1.01, 95% CI = 1.00–1.02, p = 0.010) were independently associated with RV involvement 
(Table 5). Moreover, RV GLS and RV free wall LS had incremental values for the prediction of RV involve-
ment in C-statistics. RV wall thickness with RV GLS (AUC = 0.813) and RV wall thickness with RV free wall LS 
(AUC = 0.816) demonstrated better correlation with RV involvement than only using RV wall thickness meas-
ured using echocardiography (AUC = 0.727), as shown in Fig. 2C,D.
Discussion
The main findings of the study were as follows: (1) RV involvement in patients with HCM is common (14.4%); 
(2) patients with RV involvement showed more advanced biventricular dysfunction, suggesting an indicator of 
severe HCM; (3) RV involvement and impaired RV longitudinal strain in patients with HCM showed prognostic 
values related to clinical adverse events; and (4) impaired RV GLS and RV free wall LS were more frequently 
detected in patients with RV involvement than in those without.
Many previous studies on RV involvement in HCM were sporadic case reports of severe RV hypertrophy and 
RV outflow tract  obstruction8,9, and only a few studies described the prevalence of RV involvement in HCM. 
In an early study, using transthoracic echocardiography, RV hypertrophy was reported in 44% of patients with 
 HCM10. Studies using CMR demonstrated a prevalence ranging from 1.3 to 30%, depending on the criteria of 
RV  involvement4,5,11. Our study showed a prevalence of 14.4%, with the RVMWT ≥ 7 mm on CMR. The varied 
reported prevalence of RV involvement in HCM is postulated to be a consequence of the different criteria of RV 
involvement and modalities measured.
Table 2.  Univariate and multivariate Cox proportional hazard models for primary outcomes in total study 
population (n = 256). SCD sudden cardiac death, LAVI left atrial volume index, RVSP right ventricular 
systolic pressure, LVOT left ventricular outflow tract, RV right ventricle, LV left ventricle, LVEF LV ejection 




HR (95% CI) P value HR (95% CI) P value
Age 1.02 (0.99–1.05) 0.172
Male sex 0.72 (0.35–1.47) 0.367
Atrial fibrillation 4.45 (2.24–8.83)  < .001 2.25 (1.01–5.01) 0.048
Familiar history of SCD 0.32 (0.08–1.33) 0.117
Syncope 2.55 (1.18–5.50) 0.017 2.31 (1.05–5.15) 0.038
LAVI 1.03 (1.01–1.04) 0.002 1.00 (0.98–1.02) 0.906
RVSP 1.08 (1.03–1.13) 0.001 1.02 (0.97–1.07) 0.479
E/e’ 1.05 (1.02–1.08)  < .001 1.05 (1.01–1.09) 0.012
LVOT obstruction 0.93 (0.42–2.07) 0.858
LVEF 0.93 (0.89–0.96)  < .001 0.94 (0.91–0.98) 0.005
RV involvement 4.13 (2.05–8.32)  < .001 2.30 (1.10–4.82) 0.024
LV maximal wall thickness 0.97 (0.90–1.05) 0.477
LVESV 1.01 (0.99–1.03) 0.311
RV LGE 2.06 (0.89–4.77) 0.091
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Classically, a family history of HCM-related SCD, unexplained syncope, multiple and repetitive non-sustained 
ventricular tachycardia, massive LVH, LV apical aneurysm or burn out stage (EF < 50%), and extensive LGE were 
suggested risk factors for SCD in  HCM3,12. LVOT obstruction, diastolic dysfunction, and atrial tachyarrhythmia 
were considered risk factors related to heart  failure13,14. Consistent with prior studies, our results showed that 
diastolic dysfunction, AF, unexplained syncope, and reduced LVEF were related to adverse clinical events but 
LVOT obstruction was not. We assumed that patients with high risk of SCD were managed with optimal medi-
cal therapy, ICD implantation, or septal myectomy, which may be responsible for these results. The association 
between RV involvement and poor prognosis indicated that patients with RV involvement had more advanced 
HCM and presented with significantly higher LAVI, higher E/e’, lower LVEF, and more impaired LV GLS in this 
study. LAVI and E/e’ reflect the LV end-diastolic pressure and long-term effects of elevated LV filling pressures; 
they are well correlated with LV diastolic burden and poor prognosis in patients with  HCM15–17. Moreover, 
abnormal LV GLS has been shown to occur in HCM and is associated with a worse prognosis, even in patients 
with a normal LV ejection  fraction18. Therefore, it is reasonable to assume that RV involvement is associated 
with severe systolic and diastolic dysfunction in HCM, which may play a role in determining clinical outcomes.
Figure 1.  Representative case of HCM with RV involvement. (A) Significant hypertrophy of the RV apex 
(9.2 mm) and (B) late gadolinium enhancement in the anteroseptal and inferoseptal wall were seen. (C,D) 
Impaired right ventricular two-dimensional speckle-tracking strain pattern is seen in the patient.
Table 3.  Comparison of the left and right ventricular longitudinal strain values between patients with RV 
involvement and those without RV involvement (n = 190). RV right ventricle, LV left ventricle, LS longitudinal 
strain, GLS global LS. *P value between patients with RV involvement and patients without RV involvement.
Longitudinal strain Total patients (n = 190) No RV involvement (n = 160) RV involvement (n = 30) P-value*
LV GLS, % − 11.7 ± 4.8 − 12.2 ± 4.9 − 9.5 ± 3.3 0.001
RV GLS, % − 18.6 ± 5.5 − 19.4 ± 5.3 − 14.5 ± 5.0  < .001
RV septal wall LS, % − 12.9 ± 6.4 − 13.5 ± 6.1 − 10.0 ± 7.2 0.006
RV free wall LS, % − 21.8 ± 7.1 − 22.9 ± 6.9 − 16.4 ± 5.1  < .001
RV free wall LS > − 20%, n (%) 79 (41.6%) 55 (34.6%) 24 (77.4%)  < .001
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Prior literature regarding RV in HCM has described RV structural features and dysfunction separately. Some 
studies revealed that the structural feature, RV hypertrophy, is associated with poor clinical outcomes. In addi-
tion, RV dysfunction is frequently observed in patients with HCM and is associated with an increased likelihood 
of adverse clinical  event7,19,20. Recently, Wu et al. showed that RV hypertrophy exhibits more reduced RV GLS, 
supported exercise capacity, and can independently predict exercise intolerance in patients with  HCM6. Xiang Li 
et al. also presented that impaired RV myocardial strain was more obvious in the presence of RVH and LGE in 
 RV21. Our results supported these prior studies and showed both structural abnormality and functional impair-
ment of RV using CMR imaging in a relatively large study population. Patients with RV involvement had more 
impaired RV mechanical function, and both RV involvement and impaired RV dysfunction were independently 
associated with clinical outcomes. Therefore, we assumed that RV involvement implies more severe myocardial 
dysfunction, not only of LV but also of RV.
Interestingly, our study showed a large discrepancy in RV thickness as determined using transthoracic echo-
cardiography and RVMWT on CMR imaging. We assumed this is due to the differing measurement sites and 
methods. In transthoracic echocardiography, RV thickness was calculated as the diameter of the RV free wall 
below the tricuspid annulus at a distance approximating the length of the anterior tricuspid leaflet, as recom-
mended in the current guidelines. In contrast, RVMWT on CMR imaging measured the greatest diameter of the 
Table 4.  Univariate and multivariate Cox proportional hazard model for primary outcomes in patients with 
strain echocardiography (n = 190). SCD sudden cardiac death, LAVI left atrial volume index, RVSP right 
ventricular systolic pressure, RV right ventricle, LV left ventricle, LVEF left ventricular ejection fraction, CMR 
cardiac magnetic resonance, LVESV left ventricular end systolic volume, LGE late gadolinium enhancement.
Variables
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Age 1.01 (0.98–1.04) 0.622
Male sex 0.58 (0.26–1.27) 0.173
Atrial fibrillation 5.85 (2.37–12.85)  < .001 2.15 (0.76–6.12) 0.151
Syncope 2.80 (1.16–6.74) 0.022 4.03 (1.54–10.56) 0.005
Familiar history of SCD 0.21 (0.03–1.58) 0.131
LAVI 1.03 (1.01–1.05) 0.010 0.99 (0.99–1.02) 0.245
RVSP 1.08 (1.03–1.13) 0.003 1.06 (0.99–1.13) 0.077
E/e’ 1.06 (1.02–1.09)  < .001 1.05 (1.00–1.11) 0.037
Obstructive type 0.88 (0.39–2.00) 0.761
LVEF 0.93 (0.89–0.97)  < .001 0.95 (0.91–0.99) 0.022
RV free wall LS > − 20% 4.03 (1.68–9.67) 0.002 3.07 (1.16–8.09) 0.023
LV maximal thickness 0.97 (0.90–1.05) 0.477
LVESV 1.01 (0.99–1.02) 0.630
RV LGE 1.82 (0.68–4.88) 0.232
Figure 2.  Kaplan–Meier curves for primary outcome-free survival (A) according to the presence of right 
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segments of the RV free wall, including the basal, mid, and apical levels of the RV free wall, in this study. Consid-
ering the methodological difficulty in measuring RV thickness using echocardiography, impaired RV strain is a 
more meaningful predictor of the structural change in RV and clinically adverse events in patients with HCM.
This study has several limitations. First, the retrospective study design investigated a single-centre registry; 
thus, there is a possibility of selection bias. Considering LGE was observed in > 90% of patients in our study 
population, it is suggested that many patients with advanced HCM were selected in this study. Second, the criteria 
of RV involvement can be deemed arbitrary because standard criteria for RV involvement in HCM were not 
established. Maron MS. et al. measured RV thickness using automatic software at any site within the RV wall and 
reported an average RV thickness of 7 ± 2 mm in patients with  HCM4. Nagata Y. et al. defined RV hypertrophy 
as RV maximal wall thickness > 5 mm; the average maximal RV thickness was 4.7 ± 2.3 mm in the total patient 
population and 7.8 ± 1.8 mm in patients with RV hypertrophy in their study. Based on these previous studies, 
we defined RV involvement as the maximum RV wall thickness of ≥ 7 mm. We presumed that this criterion is 
reasonable to minimize the possibility of false-positive and false-negative findings of RV involvement. Further 
large population and prospective studies are required to standardize the diagnostic criteria of RV involvement in 
HCM. Third, we could not include data of genetic testing for HCM and follow-up CMR due to the retrospective 
nature of the study. Information regarding genetic mutation and serial change in the RV phenotype orn CMR 
could provide more concomitant evidence of the mechanism of RV involvement.
In conclusion, RV involvement in patients with HCM is common. Patients with RV involvement showed 
more severe myocardial dysfunction of the LV and RV, suggesting that it can be considered an indicator of severe 
HCM. Furthermore, RV involvement and impaired RV longitudinal strain in HCM showed clinical significance 
related to adverse clinical outcomes.
Methods
Study population. A total of 346 patients who underwent both cardiac magnetic resonance (CMR) imag-
ing and transthoracic echocardiography within 6 months of each other were screened in Yonsei University Car-
diovascular Hospital in the Republic of Korea. Patients who had undergone septal myectomy, had combined 
heart disease leading to RV hypertrophy, or had significant pulmonary hypertension defined as RV systolic 
pressure (RVSP) > 50 mmHg were excluded. Finally, 256 patients were included for the analysis. The study was 
approved by the Institutional Review Board of the Yonsei University Health System (approval number: 4-2012-
0655), and it complied with the ethical principles of the Declaration of Helsinki. The need for informed consent 
was waived by the local ethics committee of the Yonsei University Health System.
Cardiac magnetic resonance imaging. All patients underwent CMR with a 3-T clinical scanner (Mag-
netom Trio Tim, Siemens AG Healthcare Sector, Erlangen, Germany). Electrocardiogram gated cine images 
were acquired in the short-axis views using retrospective echocardiography-gated balanced steady-state free 
precession true fast imaging with steady-state precession (TrueFISP) sequence with the following parameters: 
repetition time (TR), 3.3 ms; echo time (TE), 1.44 ms; flip angle, 50°, 25 phases; slice thickness, 8 mm; slice 
gap, 8 mm; acquisition matrix, 216 × 256 pixels; and field of view, 337 × 400  mm2. LV and RV LGE images were 
acquired 10 min after contrast injection (0.2 mmol/kg of a gadolinium-based contrast media) using a magni-
tude- and phase-sensitive inversion-recovery-prepared TrueFISP sequence, with the inversion time adjusted 
to null, thus representing the normal myocardium. Two expert radiologists, blinded to patients’ clinical data, 
analysed CMR images. All image analyses were performed using semi-automatic segmentation in the software 
(CMR42, Circle Cardiovascular Imaging, Calgary, Alberta, Canada). Additionally, the left and right ventricular 
Table 5.  Univariate and multivariate logistic regression analysis to estimate association between 
echocardiographic parameters and right ventricular involvement in hypertrophic cardiomyopathy. OR odds 
ratio, CI confidence interval, LAVI left atrial volume index, RVSP right ventricular systolic pressure, LVOT 
left ventricular outflow tract, LVEF left ventricular ejection fraction, LV left ventricle, RV right ventricle, GLS 
global longitudinal strain, LS longitudinal strain.
Variables
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
LAVI 1.01 (1.00–1.01) 0.008 1.00 (0.99–1.00) 0.179
RVSP 1.01 (0.99–1.01) 0.084
E/e’ 1.01 (1.00–1.02) 0.013 1.00 (0.99–1.01) 0.448
LVOT obstruction 1.05(0.93–1.19) 0.423
LVEF 0.99 (0.99–1.00) 0.299
LV GLS 1.03 (1.02–1.04)  < .001 1.01 (1.00–1.03) 0.034
RV GLS 1.02 (1.01–1.03)  < .001
RV septal LS 1.02 (1.01–1.03)  < .001
RV free wall LS 1.02 (1.01–1.02)  < .001 1.01 (1.00–1.01) 0.046
RV thickness 1.12 (1.08–1.15)  < .001 1.09 (1.06–1.12)  < .001
LV maximal thickness 1.03 (1.02–1.04)  < .001 1.01 (1.00–1.02) 0.010
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volumes and ejection fractions (EFs) were measured from the cine images using semi-automatic segmentation 
in the software (CMR42, Circle Cardiovascular Imaging, Calgary, Alberta, Canada). LV (LVMWT) and RV 
(RVMWT) maximal wall thickness were measured as the greatest dimension at end-diastole measured manu-
ally in short-axis slices. RVMWT was measured in the segments of the RV free wall, as shown in Fig. 3A. The 
presence of LGE in LV and RV was also confirmed separately (see Fig. 3B). Pericardium and trabeculations were 
excluded from the assessment of wall thickness. RV involvement was defined as maximum RV wall thickness 
of ≥ 7 mm in any segments of the RV free wall.
Echocardiography. Two-dimensional linear and volumetric measurements were obtained using standard 
 methods22,23. LVMWT was determined at end-diastole from the parasternal short-axis view. RV wall thickness 
was measured at end-diastole below the tricuspid annulus at a distance approximating the length of the anterior 
tricuspid  leaflet24. Obstruction of the LV outflow was defined as the peak pressure gradient of the LV outflow 
tract ≥ 30 mmHg on continuous-wave Doppler echocardiography at rest or by Valsalva manoeuvre. In a sub-
group analysis, LV and RV mechanical function were evaluated in 190 patients using speckle tracking echocar-
diography (STE). LV and RV strain were assessed via STE analysis performed offline using customized software 
(EchoPAC PC; GE Medical Systems). Three consecutive cardiac cycles were recorded and averaged, and frame 
rates were set to 60–80 frames per second. LV global longitudinal strain (GLS) was obtained from the average of 
three standard apical views. RV GLS was defined as the average of the RV free wall and septal segments measured 
in standard focused RV view or apical four-chamber view using the software designed for LV measurements and 
adapted for the RV. RV free wall longitudinal strain (LS) was defined as the arithmetical average of three seg-
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Figure 3.  Scatter plot and Pearson correlation coefficient between (A) right ventricular maximal wall thickness 
(RVMWT) and RV global longitudinal strain (GLS) and (B) RVMWT and RV free wall longitudinal strain (LS). 
Comparison of receiver operating characteristic curves with corresponding areas under the curve to predict RV 
involvement between (C) RV wall thickness and RV wall thickness with RV GLS and (D) RV wall thickness and 
RV wall thickness with RV free wall LS.
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ments (base, mid, and apex) of the RV free wall (see Fig. 3C,D). Impaired RV free wall longitudinal strain was 
defined as > − 20%23,25.
Outcomes. Primary outcomes were defined as composite of all-cause death, heart transplantation, and cardi-
ovascular hospitalization during the follow-up period (median: 1153 days [interquartile range: 748–1372 days]). 
A cardiovascular hospitalization was defined as an unplanned cardiovascular event requiring admission for 
heart failure, angina, atrial or ventricular tachyarrhythmia, sudden collapse, stroke, or myocardial infarction. 
The clinical events were analysed by two researchers independently, and the occurrence of renal outcomes was 
decided with the agreement of both researchers.
Statistical analysis. All continuous data are presented as mean ± standard deviation, and categorical 
data are expressed as numbers and percentages for each group. Interobserver agreement for the presence of 
RV involvement was calculated using Cohen’s kappa value. The significance of RV involvement on primary 
outcomes was analysed with multivariate Cox proportional hazard models and Kaplan–Meier curves. Correla-
tion between RVMWT and parameters of LV and RV strain was calculated using Pearson’s correlation method. 
Diagnostic incremental values of the echocardiographic parameters identifying RV involvement were estimated 
using receiver operating characteristic (ROC) curves with corresponding areas under the curve (AUC). Com-
parisons between the AUC were conducted using DeLong’s  test26. All tests were two-sided, and statistical signifi-
cance was defined as p < 0.05. All statistical analyses were performed with R statistical software (version 3.6.0; R 
Foundation for Statistical Computing, Vienna, Austria).
Data availability
All data used during this study will be available from the corresponding author if the request is rational.
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